Results from randomly treated tumors showed that for animals with high tumor burden, adding systemic (intraperitoneally (IP)) doses of anti-PD1, anti-CTLA4, and both together, respectively, improve the overall survival (Figure 4B) with no significant reduction of tumor volumes (Figure 4C), including body weight (Figure 4D) and body score (Figure 4E). The gene discussed is CTLA4; the disease is neoplasm.